Biosimilars

Brain Cancer

Breast Cancer

Business Management

CAR T-cell Therapy

COVID-19

Chronic Lymphocytic Leukemia

Colorectal Cancer

Disparities in Cancer Care

Gastrointestinal Cancer

Genitourinary Cancers

Global Oncology

Gynecologic Oncology

Head & Neck Cancers

Hematologic Oncology

Immuno-Oncology

Lung Cancer

Mantle Cell Lymphoma

Melanoma & Skin Cancer

Multiple Myeloma

Myeloproliferative Neoplasms

Neoadjuvant HER2+

Non-Hodgkin Lymphoma

Oncology Nursing News

Ovarian Cancer

Pediatric Oncology

Precision Medicine in Oncology®

Prostate Cancer

Sarcomas/TGCT

Supportive Care

Urothelial Cancer

Up-front treatment with osimertinib reduced the risk of brain progression-free survival but provided a comparable overall survival benefit compared with sequential treatment with gefitinib followed by osimertinib in patients with advanced non–small cell lung cancer harboring EGFR mutations.

Up-Front Osimertinib Provides Comparable OS, Improved Brain PFS Vs Sequential Gefitinib/Osimertinib in EGFR+ NSCLC

Dimitrios Nasioudis, MD, discusses how the use of next-generation sequencing can help identify the unique molecular profile of endometroid ovarian cancer. 


Dr Nasioudis on the Use of NGS to Identify the Molecular Profile of Endometroid Ovarian Cancer

Lindsay K. Buckingham, MD, discusses an investigation into the use of patient-reported outcomes from the cancer-specific Geriatric Assessment (GA) to predict frailty in women with ovarian cancer, as well as planning the next steps for this research in other gynecologic cancers.
 

Dr Buckingham on the Use of Patient-reported Outcomes to Predict Frailty in Patients With Ovarian Cancer

Brian M. Slomovitz, MD, discusses the evaluation of letrozole and ribociclib from the phase 2 GOG 3026 trial in recurrent low-grade serous ovarian carcinoma.

Dr Slomovitz on the Investigation of Letrozole Plus Ribociclib in Low-Grade Serous Ovarian Carcinoma

News

OncClub

All Oncology News

Pipeline Report

Media

Insights

Medical World News

OncChats

OncLive News Network®

OncLive TV

Peer Exchange

Podcasts

Rapid Readouts

The Talk

Conferences

Conference Coverage

Conference Listing

Events

Giants of Cancer Care

PER Events

Scientific Interchanges

State of the Science Summit / IPC

Webinars

Partners

Publications

OncologyLive

Oncology Fellows

Supplements And Featured Publications

All Publications

CME/CE

Resources

Interactive Tools

Learning Modules

Presentations

Subscribe

Print Subscription

eNewsletter

joined MJH Life Sciences in 2016 and has since held several positions within the company. She helped launch the rapidly growing infectious disease news resource 

, and now serves as the main digital news writer for 

. Prior to working at the company, she served as lead copywriter and marketing coordinator at The Strand Theater. Email: krosa@onclive.com

Articles

The FDA has granted full approval to pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability–high or mismatch repair–deficient solid tumors that have progressed following previous treatment and who have no satisfactory alternative options. 

FDA Grants Full Approval to Pembrolizumab for Select Patients With MSI-H or dMMR Solid Tumors

Neeraj Agarwal, MD, discusses preclinical data that supported the launch of the TALAPRO-2 trial and key efficacy and safety data on the use of talazoparib plus enzalutamide in patients with metastatic castration-resistant prostate cancer irrespective of homologous recombination repair mutational status.

TALAPRO-2 Data Underscore Potential of Talazoparib Plus Enzalutamide in mCRPC

Dana-Farber Cancer Institute researchers outline the complexities of colorectal cancer and the research needed to map out a path toward understanding it. 

Dana-Farber Researchers Chart a Course for Understanding, Preventing, and Treating Young-onset Colorectal Cancer

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

Ivan Marques Borrello, MD, Johns Hopkins University

Articles

Latest Conference Coverage